Spinraza: Biogen announced new results from the NURTURE study

  • After up to 4.8 years of continuous treatment with SPINRAZA, 100 percent of children treated pre-symptomatically were alive, and none require permanent ventilation
  • Patients continued to maintain and make progressive gains in motor function compared to the natural history of the disease, with 96 percent now able to walk with assistance
  • The NURTURE study was recently extended to evaluate the longer-term efficacy and safety of SPINRAZA up to 8 years of age
  • Read more

New Data to the SHINE open-label extension study

Biogen releases new data from the Shine study (NCT02594124). The has enrolled 292 patients (infants through teenagers) from five previous SPINRAZA clinical studies, including ENDEAR. New findings from the SHINE study show treatment with SPINRAZA resulted in motor function improvement or disease stabilization in toddlers, children and young adults who were treated continuously, some for up to six and a half years.

Read more